Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP10 | Q14694 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.40 |
| ▸ | USP19 | O94966 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923580 | 0.90 | MAPT (0.50) | USP10ALDH1A1MAPTHTTGRIN2B | |
| SCHEMBL1923726 | 0.89 | MAPT (0.51) | USP10ALDH1A1MAPTHTTGRIN2B | |
| SCHEMBL1923740 | 0.89 | KMT2A (0.41) | USP10MEN1KMT2AALDH1A1CYP46A1 | |
| SCHEMBL1923300 | 0.88 | USP10 (0.49) | USP10KMT2AALDH1A1MAPTHTT | |
| SCHEMBL1923398 | 0.88 | USP10 (0.49) | USP10CREBBPALDH1A1MAPTHTT | |
| SCHEMBL1923418 | 0.87 | ATM (0.51) | USP10MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1924841 | 0.84 | ALDH1A1 (0.53) | USP10MEN1KMT2AALDH1A1GRIN2B | |
| SCHEMBL1923600 | 0.83 | SMN1; SMN2 (0.46) | USP10KMT2AALDH1A1HTTGRIN2B | |
| SCHEMBL1923374 | 0.83 | USP10 (0.44) | USP10ALDH1A1MAPTHTTGRIN2B | |
| SCHEMBL1924088 | 0.81 | PTGDR2 (0.47) | USP10KMT2AALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | claimed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | claimed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | claimed |
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | disclosed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | GABRA1, GABRA4, GABRA2 | USP10 3340/4885MEN1 3307/4885KMT2A 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.